Acadia Pharmaceuticals Stock News

ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.

A positive clinical readout is lighting a fire underneath the biotech's shares today.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome Acadia Pharmaceuticals Inc. (N

(RTTNews) - The following are some of the stocks making big moves in Tuesday''s pre-market trading (as of 07.05 A.M. ET). In the Green Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13%

H.C. Wainwright Stick to Their Hold Rating for ACADIA Pharmaceuticals

The stock price of Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) increased by over 15% pre-market today. This is why it happened.

A positive clinical readout is lighting a fire underneath the biotech's shares today.

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from Phase 3 Lavender study of trofinetide in Rett syndrome. The 12-week study demonstrated a statistically significant improveme

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome. The 12-week placebo-controlled study demonstrated a statistically significant improvement over placebo for both co-primary endpoints. On the Rett Syndrome Behaviour Questionnaire (RSBQ), change from baseline to week 12 was -5.1 v

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded at $19.20 at close of the session on Tuesday, 11/30/21, made an upward move of 1.91% on its previous days price. Looking at the stock we see that its previous close was $18.84 and the beta (5Y monthly) reads 0.74 with the days price range being $18.57 $19.24. In ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Is On The Rise Read More »

Acadia Healthcare's (ACHC) buyouts are helping the company to add facilities, beds and hospitals to its network and contributing to its top line.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 2,803 shares of the companys stock in a transaction dated Monday, November 22nd. The stock was sold at an average price of $19.01, for a total value of $53,285.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through []

Here are the five best biotech ETFs to invest in right now.

Key Companies in Parkinsons Disease Drugs Market are Pfizer, Roche, Merck, Novartis, Orion Pharma, UCB, Teva Pharmaceutical, Vertical Pharmaceuticals, ACADIA Pharmaceuticals Inc., Impax Laboratories, Lundbeck and Others Key Players Key Companies in Parkinsons Disease Drugs Market are Pfizer, Roche, Merck, Novartis, Orion Pharma, UCB, Teva Pharmaceutical, Vertical Pharmaceuticals, ACADIA Pharmaceuticals Inc., Impax Laboratories, Lundbeck and Others Key Players